Novo To Secure Licensing Or M&A Deal By Mid-2018
Executive Summary
Who is on Scrip’s list of potential licensing partners and M&A targets for Novo Nordisk, now that the company has renewed its hunt for new products to add to its hematology portfolio?
You may also be interested in...
Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons
Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.
Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign
Sanofi's €3.9bn acquisition of Ablynx will allow the French big pharma to build up its rare blood disorder pipeline and bring in complementary programs in areas like respiratory infections.
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.